Skip to search formSkip to main contentSkip to account menu

crizotinib

Known as: (R)-Crizotinib, 2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-, (R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine 
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth… 
National Institutes of Health

Related topics

Related topics

11 relations
ALK protein, humanNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]

Narrower (2)

PF-2341066Xalkori

Broader (3)

Protein Kinase InhibitorsPyrazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Efficacy of Alectinib in Patients with ALK‐Positive NSCLC and Symptomatic or Large CNS Metastases
Review
2017
Review
2017
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
LBA9008Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-naive/resistant ALK+ NSCLC. J-ALEX… 
2016
2016
High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
Review
2016
Review
2016
Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from…
Corresponding author: Dr Alice T Shaw, Massachusetts General Hospital, 32 Fruit Street, Boston, MA, 02114, Phone: 617 724 4000… 
2016
2016
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
A study reported in this issue of The Oncologist examined the utility of next-generation sequencing (NGS) in detecting ALK… 
Highly Cited
2015
Highly Cited
2015
Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.
8065 Background: Molecular alterations of crizotinib (crz) targets (ALK, MET, ROS1) are found in a wide range of malignancies. To… 
Review
2014
Review
2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian…
2014
2014
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design.
  • B. PascheS. Grant
  • Journal of the American Medical Association (JAMA…
  • 2014
  • Corpus ID: 205058905
Historically, lung cancer has been categorized, based on histology, into non–small cell lung cancer (NSCLC) constituting… 
2013
2013
A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.
2011
2011
Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
e13065 Background: Crizotinib is a selective, ATP-competitive, small molecule inhibitor of the ALK and MET/HGF receptor tyrosine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)